济南看男性专科医院济南男科医院那一家好,济南男生龟头太敏感怎么办,济南哪家医院治疗男科比较好,济南阴茎出尿口上口粘连是什么原因,济南前列腺炎不治会怎样,济南包皮内长疙瘩是怎么回事,济南用什么中药可以治早泄

The end of net neutrality is now scheduled for next month.The Federal Communications Commission said in a notice filed Thursday that new rules repealing the net neutrality protections are set to take effect 30 days from this Friday, or June 11."Now, on June 11, these unnecessary and harmful internet regulations will be repealed and the bipartisan, light-touch approach that served the online world well for nearly 20 years will be restored," Ajit Pai, chairman of the FCC, said in a statement Thursday.The Republican-led FCC voted along party lines in December to repeal the Obama-era net neutrality rules, which were intended to prevent internet providers from blocking, speeding up, or slowing down access to specific online services.The FCC previously said that parts of the repeal order would take effect on April 23. The rest of the order required the approval of the Office of Management and Budget, which the FCC says it received earlier this month.The new timeline comes as net neutrality advocates make a last ditch effort to undo the repeal.Related: Trump administration sends mixed messages on big mediaSenate Democrats are currently pushing for a vote on a bill to overturn the decision as soon as next week. Even if the resolution passes the Senate, it still faces an uphill battle in the House.Gigi Sohn, a counselor to former FCC chairman Tom Wheeler, recently told CNN that the future of net neutrality will likely "stay murky" through the remainder of this calendar year, "at the very least."More than 20 states have filed a lawsuit to stop the net neutrality repeal. Several states, including New Jersey, Washington, Oregon and California, have gone so far as to push legislation to enforce the principles of net neutrality within their borders.This local legislation could lead to a legal showdown, however.A spokeswoman for the FCC previously directed CNNMoney to a section of the final order for net neutrality, in which the FCC asserts authority to prevent states from pursuing laws inconsistent with the net neutrality repeal."You do have a number of states who have passed rules and they haven't really implemented them because if they do they will be sued by the operators."It's patently illegal for the states to make their own internet policy," says Roslyn Layton, a visiting scholar at the American Enterprise Institute who served on President Trump's transition team for the FCC.Layton expects telecommunications companies will sue the states if they try to enforce the protections.  2527

The coronavirus pandemic has already caused depleted toilet paper shelves and concerns about meat shortages, but now it’s also to blame for some other, maybe more surprising shortages across the country.Coca-Cola announced at the beginning of July that it was stopping production on Odwalla Juice at the end of the month. On a call with investors, James Quincey, Chairman & Chief Executive Officer of The Coca-Cola Co. said of Odwalla, “In the case of a brand like Odwalla and its chilled direct store delivery, which has struggled over the last several years, we started to stop operations effective July 31. This gives us the flexibility to support our investments in brands like Minute Maid and Simply.”And if you thought you were imagining fewer types of Coke products on store shelves, there’s a good chance you weren’t. A representative from the soft drink giant said in an email, “We continue to see high demand for products consumed at home. We are implementing contingency plans as best we can to get the products people want to store shelves. We appreciate everyone’s patience as we work through these unprecedented times,” going on to say, “we are focusing on the availability of our most popular brands.”“Coke is facing is a different sort of thing right now; it's something that's a shift in demand, which is temporary, and they're not in position to respond to it other than to…put all of their eggs into the baskets that are going out the door fastest,” said William Dickens, University Distinguished Professor and chair of the economics department at Northeastern University.Another issue for Coke likely ties into another shortage – aluminum cans.According to Robert Budway, the president of the Can Manufacturers Institute, the aluminium can industry was seeing demand increase even before the pandemic began because cans are more environmentally friendly than plastic bottles, and the demand has only gone up.“Can manufacturers are fully focused on filling the extraordinary demand from all sectors of the industry’s customer base,” said Budway in a statement. He also said that although there is enough aluminum, can makers have announced the construction of several new plants in the United States and Canada, but they will take between 12 and 18 months to build.Chains like Taco Bell announced they’re trimming the menu too, removing things like the 7-Layer Burrito and Nachos Supreme. And Red Robin Gourmet Burgers ditched a third of its menu.The national burger chain cut 55 items, and a representative pointed to what they told their investors about the changes saying the cuts have resulted in “faster cook times, higher quality food” and say it’s reduced waste.“Sure,” said Dickens. “But why wouldn't they have done it before this, if it made such a big difference? The best explanation is that now they're in a different circumstance, and they just can't afford to produce the type of variety that they did before because they aren't having as many people coming in.”Dickens said everything, each menu item and each flavor of soda, has a specific cost to make. For a business to be profitable, it has to sell a certain number of each offering.So it makes sense that less popular items might hit the road right now.“As for menus and shortages…I think we may very well see more firms follow suit. I know my favorite restaurant is only offering a couple of items compared to what it used to. So I know it's a phenomenon that's out there,” said Dickens. “It's more profitable for [restaurants] to focus on a couple of items that they know that they're going to sell a lot of.”He went on to say what we can expect to see in the next month or year largely depends on how things go with COVID-19 and the subsequent handling of the economy.“I guess my biggest fear is that we're mishandling the economy,” said Dickens.He said that the United States’ economy hasn’t shrunk as much as it might have since the pandemic hit because Congress authorized an extra 0 per week for unemployment benefits. He said that the people who are getting those benefits are also then spending that money on things like food and drink.With the final unemployment supplements already distributed, Dickens predicts people will have less money to spend, which in turn will mean less money in the economy overall, more job layoffs – and a deeper recession. He said that could ultimately mean more shortages – and more businesses closing for good.“We should not let the smart things that were done fade away too early, and this is clearly too early since a large part of the country is still seeing growing numbers of cases,” said Dickens. “They're probably going to have to take action to pull back from re-opening and people are gonna need economic support.” 4769

The final countdown is on and everything has been meticulously planned down to the final detail.But there is one wild card that even the Queen herself cannot control: What will the weather be for Prince Harry and Meghan Markle's big day on Saturday, May 19?Since we are still 10 days out, it's still too early to make a definitive call on rain or give detailed predictions about the timing of any potential showers -- but we can look at the long-range weather models and get an idea of what the general weather pattern will be while the world's eyes are on England.May's weather is off to a perfect start, with clear skies and well-above average temperatures in London nearing 30? C (86? F), which has locals feeling the royal wedding fever.The average high temperature for May in London is 18? C (64? F), so this past week has felt downright summer-like.A change in the weather threatens to dampen spirits, however, with cooler temperatures and several bouts of rain moving through in the next week as we lead up to wedding weekend.Temperatures will plummet to below average with significantly more clouds and some rain in the forecast as a couple of low pressure systems move through the British Isles next week.Fortunately, the weekend looks like it could see a return of the milder air and potentially clearer skies as high pressure builds over the North Sea.According to the UK Met Office, the nation's weather forecasting service, "there is low confidence in the forecast for the rest of next week and the following weekend, but there are some signals that it may turn drier, more settled and somewhat warmer with light winds."The forecast for the day can, and likely will, change over the next week and a half. Weather forecasts more than a week out have considerably less skill than short-term forecasts of just a couple of days.Especially when dealing with a region that has rapidly changing weather conditions like Great Britain.A dry wedding day would fit in line with other recent royal nuptials, including those of Prince William and Catherine Middleton in April of 2011 and Prince Charles and Diana's in July, 1981, both of which avoided the damp and rainy conditions many associate with British weather. 2226

The decision to forego local bubbles was jointly recommended by NFL and NFLPA medical experts based on COVID testing data. They’re happy with the numbers and sticking with what works. Here’s the full memo, which also updates return to play protocols, etc. pic.twitter.com/GQxF0IF3jt— Tom Pelissero (@TomPelissero) December 15, 2020 345

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug's risks.In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis.The medication has been cited as a so-called "suspect" medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago."What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid."How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"Tracked by the FDA, the adverse event reports cited by DeLauro do not mean that a suspected medication has been ruled the cause of harm and are typically not the result of official investigations. But the FDA uses the information to monitor potential issues with a drug and can take action as needed: updating a medication's label, for instance, or restricting its use. In rare cases, the agency can even pull a drug off the market.When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.But physicians, researchers and other medical experts told CNN that the high number of reports deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.Nuplazid's review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.Dr. Paul Andreason, the physician who led the FDA's medical review of Nuplazid, warned that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.At that advisory committee meeting two years ago, one woman said that her grandmother had been part of the clinical trials for the drug and that Nuplazid had been life-changing."We didn't know what to expect or even if she was on the drug" or a placebo, said Zoey Wade. "We soon realized that she must be taking the drug, because she really returned to herself. Her hallucinations reduced, and she better understood what was real and what was imaginary."Shortly after Nuplazid's release, however, patients' family members, doctors and other health care professionals started reporting "adverse events" possibly linked to the medication -- including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue.During the first 10 months Nuplazid was on the market, 244 deaths were reported to the FDA in which Nuplazid was a "suspect" medication, according to an analysis conducted by the Institute for Safe Medication Practices. FDA data now show that the number of reported deaths has risen to more than 700. In more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid.After CNN published its investigation on Nuplazid, reporters were contacted by family members who said the drug helped tame hallucinations with few apparent side effects and others who said they believe Nuplazid contributed to their family member's decline or death. Some said they had not yet reported these experiences to the drugmaker or the FDA.While the FDA has long been criticized for being too slow to approve drugs, DeLauro seized on its push to streamline the process, lambasting the agency for putting industry interests and efficiency above public health and safety.DeLauro described the number of adverse events and deaths as "staggering" and "unprecedented." She also expressed concern that the drugmaker, Acadia Pharmaceuticals, is attempting to get the drug approved for a larger population: patients who suffer from dementia-related psychosis."I don't know why it should stay on the market, especially when the FDA has not determined it to be safe and while the number of adverse events continues to soar," she told Gottlieb.In response to the congresswoman's remarks, Acadia told CNN that adverse event data alone are "not a comprehensive and accurate indicator of the safety profile of any drug." In response to CNN's earlier report on the drug, Acadia said there are a number of reasons for the higher volume of death reports, including the fact that the company distributes Nuplazid through a network of specialty pharmacies that puts the company in more frequent contact with both patients and caregivers -- meaning Acadia is more likely to receive reports of death, which it is required to pass along to the FDA.Commissioner Gottlieb told the committee that the FDA is careful about the decisions it makes and that there may be a higher tolerance for risk in situations where there is an unmet medical need, "so long as the patient is properly informed of what those risks are." This echoed what he told CNN's Dr. Sanjay Gupta in an interview earlier this month.The FDA previously told CNN that it was aware of Nuplazid's "complex safety profile" at the time of approval and required the drugmaker to place warnings on its labeling. The agency also said that, though it was continuing to monitor available information about Nuplazid, it had "not identified a specific safety issue" not already reflected on the medication's label.DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid. 7224